Skip to content

Advertisement

  • Erratum
  • Open Access

Erratum to: Patient preferences for treatment of castration-resistant prostate cancer in Japan: a discrete-choice experiment

  • 1,
  • 2,
  • 3,
  • 4,
  • 5,
  • 6,
  • 7,
  • 6,
  • 6,
  • 7,
  • 6,
  • 5 and
  • 5Email author
BMC UrologyBMC series – open, inclusive and trusted201717:20

https://doi.org/10.1186/s12894-017-0210-x

  • Received: 21 March 2017
  • Accepted: 21 March 2017
  • Published:

The original article was published in BMC Urology 2016 16:63

Erratum

After publication of this work [1] it was noticed that there was a typographical error in the Conclusions. The letter ‘a’ in ‘asymtoptomatic’ should have been removed in the concluding statement as it is inconsistent with the Results and Discussion. The statement in the Conclusions should read: ‘Patients who were symptomatic placed significantly more importance on delaying an SSE when expressing medication preferences.’

The original article was corrected. The publisher apologises for this error.

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan
(2)
Division of Breast and Medical Oncology, National Cancer Center Hospital East, Chiba, Japan
(3)
Department of Urology, Nippon Medical School, Tokyo, Japan
(4)
Division of Urology, Harasanshin General Hospital, Fukuoka, Japan
(5)
Bayer Yakuhin, Ltd., 2-4-9, Umeda, Kita-ku, Osaka 530-0001, Japan
(6)
Kantar Health, New York, NY, USA
(7)
Bayer Healthcare, Whippany, NJ, USA

Reference

  1. Uemura H, Matsubara N, Kimura G, Yamaguchi A, Ledesma DA, DiBonaventura M, et al. Patient preferences for treatment of castration-resistant prostate cancer in Japan: a discrete-choice experiment. BMC Urol. 2016;16:63.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement